Global Cardiovascular & Soft Tissue Repair Patch Markets, 2027 -

The "Cardiovascular & Soft Tissue Repair Patch - Global Market Outlook (2019-2027)" report has been added to's offering.

The Global Cardiovascular & Soft Tissue Repair Patch market accounted for $3.62 billion in 2019 and is expected to reach $7.88 billion by 2027, growing at a CAGR of 10.2% during the forecast period.

High prevalence of congenital heart diseases such as atrial septal defect and technological advancements are the major factor propelling market growth. However, low awareness among consumers for the patches and high prices of procedures is hampering market growth.

Based on the application, the soft tissue repair segment is likely to have a huge demand due to the growing prevalence of various types of hernias. A hernia is a disorder where an organ or any fatty tissue bulges out through an abnormal opening. Soft tissue repair patches help in diagnosing the hernia disorder.

By geography, Asia-Pacific is estimated to have a lucrative growth during the forecast period due to the increasing prevalence of congenital heart disease and hernia. Increasing concerns about early detection and prevention of congenital cardiac disease have led to the increase of different treatment options, such as cardiac patch implantation.

Some of the key players profiled in the Cardiovascular & Soft Tissue Repair Patch Market include Admedus, Edward Life Science Corporation, Glycar SA Pty Ltd, Gunze Limited, Labcor, Lemaitre Vascular Inc, Maverick Bioscience, Neovasc, Atriummed, B.Braun, Bard Peripheral Vascular Inc, Baxter, Biointegral Surgical, Inc, Cormatrix and Cryolife, Inc.

What the report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company Profiling with detailed strategies, financials and recent developments
  • Supply chain trends mapping the latest technological advancements

Key Topics Covered

1 Executive Summary

2 Preface

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 Product Analysis

3.7 Application Analysis

3.8 Emerging Markets

3.9 Impact of COVID-19

4 Porters Five Force Analysis

5 Global Cardiovascular & Soft Tissue Repair Patch Market, By Raw Material

5.1 Introduction

5.2 Biomaterial and Tissue Engineered Material

5.3 ePTFE

6 Global Cardiovascular & Soft Tissue Repair Patch Market, By Product

6.1 Introduction

6.2 Synthetic Patch

6.3 Biologic Patch

6.3.1 Allogeneic Patch

6.3.2 Xenogeneic Patch

7 Global Cardiovascular & Soft Tissue Repair Patch Market, By Application

7.1 Introduction

7.2 Soft Tissue Repair

7.2.1 Defects of the Abdominal Wall

7.2.2 Defects of the Thoracic Wall

7.2.3 Gastric Binding

7.2.4 Hernias

7.3 Dural Repair

7.4 Pericardial Repair

7.5 Cardiac Repair

7.5.1 Atrial Septal Defect

7.5.2 Common Atrium

7.5.3 Defects of the Endocardial Cushion

7.5.4 Right Ventricular Outflow Tract Reconstruction

7.5.5 Suture Bleeding

7.5.6 Tetralogy of Fallot

7.5.7 Ventricular Septal Defect

7.6 Vascular Repair & Reconstruction

7.6.1 Anomalous Connection of the Pulmonary Veins

7.6.2 Carotid Endarterectomy

7.6.3 Reconstruction of Portal and Superior Mesenteric Veins

7.6.4 Transposition of the Great Vessels

8 Global Cardiovascular & Soft Tissue Repair Patch Market, By Geography

8.1 Introduction

8.2 North America

8.3 Europe

8.4 Asia-Pacific

8.5 South America

8.6 Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures

9.2 Acquisitions & Mergers

9.3 New Product Launch

9.4 Expansions

9.5 Other Key Strategies

10 Company Profiling

10.1 Admedus

10.2 Edward Life Science Corporation

10.3 Glycar SA Pty. Ltd.

10.4 Gunze Limited

10.5 Labcor

10.6 Lemaitre Vascular Inc.

10.7 Maverick Bioscience

10.8 Neovasc

10.9 Atriummed

10.10 B.Braun

10.11 Bard Peripheral Vascular Inc.

10.12 Baxter

10.13 Biointegral Surgical, Inc.

10.14 Cormatrix

10.15 Cryolife, Inc.

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.